Table 2.
Data at baseline and after 12 months of treatment with semaglutide
| Characteristics | Baseline (n = 122) | 12 months(n = 115) | Change after 12 monthsa | P-value |
|---|---|---|---|---|
| Glucose (mg/dl), mean ± SD | 148 ± 52.44 | 122.84 ± 25.96 | −25.95 ± 47.53 | <.001 |
| HbA1c (%), mean ± SD Patients with HbA1c <7, n (%) Mild hypoglycemia, n (%) |
7.57 ±1.36 44 (36) |
6.83 ± 0.85 66 (57.4) 9 (7.4) |
−0.73 ± 1.09 | <.001 |
| Basal insulin (IU), mean ± SD | 44.19 ± 8.37 | 32.41 ± 8.98 | −11.78 ± 15.17 | <.005 |
| Rapid-acting insulin (IU), mean ± SD | 22.35 ± 9.35 | 14.58 ± 9.89 | −7.77 ± 11.93 | .43 |
| Weight (kg), mean ± SD | 98.72±16.80 | 91.53±16.42 | −6.95 ± 6.00 | <.001 |
| BMI (kg/m2), mean ± SD Weight loss >5%, n(%) |
35.8 ± 4.79 |
33.33 ± 4.77 68 (59) |
−2.54 ± 2.22 | <.001 |
| UACR (mg/g), mean ± SD UACR (mg/g), median (Q1–Q3) |
349.49 ± 863.16 78.5 (26−199.5) |
187.28 ± 497.39 40 (6−103) |
−162.21 ± 365.77 |
<.001 <.001 |
| eGFR (CKD-EPI;mL/min/1.73 m2), mean ± SD | 50.32 ± 19.21 | 52.55 ± 19.26 | 2.2 ± 0.38 | .07 |
| Systolic BP (mmHg), mean ± SD | 129.95 ± 11.27 | 120.09 ± 09 | −9.85 ± 13.34 | <.001 |
| Diastolic BP (mmHg), mean ± SD | 77.05 ± 8.95 | 71.12 ± 7.83 | −5.92 ± 7.43 | <.001 |
| Hypertensive medications/patient, n (%) RAS blockade, n (%) |
1.61 (98.4) 117 (95.9) |
1.49 (95.9) 115 (95) |
||
| LDL cholesterol (mg/dl), mean ± SD | 80.47 ± 32.50 | 69.68 ± 23.67 | −10.79 ± 28.21 | <.001 |
| TG (mg/dl), mean ± SD | 190.67 ± 113.20 | 161.51 ± 94.76 | −29.15 ± 91.47 | .001 |
| Lipid-lowering medications/patients, n Statins,bn (%) Fibrates |
1.0 116 (95.1) 28 (22.9) |
1.06 120 (98.4) 20 (17.4) |
||
| Semaglutide withdrawal, n (%) | 7 (5.7) |
Q1: quartile 1; Q3: quartile 3; LDL: low-density lipoprotein; TG: triglycerides.
aFinal-initial.
bIncludes ezetimibe.